HARPOON THERAPEUTICS INC's ticker is HARP and the CUSIP is 41358P106. A total of 51 filers reported holding HARPOON THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,231 | +18.0% | 3,142 | +23.6% | 0.00% | – |
| Q1 2023 | $1,891 | +1.9% | 2,542 | 0.0% | 0.00% | – |
| Q4 2022 | $1,856 | -7.2% | 2,542 | +1.2% | 0.00% | – |
| Q3 2022 | $2,000 | +100.0% | 2,511 | +294.8% | 0.00% | – |
| Q2 2022 | $1,000 | -93.3% | 636 | -79.5% | 0.00% | – |
| Q1 2022 | $15,000 | -74.6% | 3,102 | -60.5% | 0.00% | – |
| Q4 2021 | $59,000 | +1375.0% | 7,856 | +1622.8% | 0.00% | – |
| Q3 2021 | $4,000 | -95.8% | 456 | -93.4% | 0.00% | – |
| Q2 2021 | $96,000 | +540.0% | 6,871 | +837.4% | 0.00% | – |
| Q1 2021 | $15,000 | – | 733 | +3757.9% | 0.00% | – |
| Q4 2020 | $0 | -100.0% | 19 | -99.4% | 0.00% | – |
| Q3 2020 | $53,000 | -53.1% | 3,144 | -53.8% | 0.00% | – |
| Q2 2020 | $113,000 | +24.2% | 6,800 | -13.0% | 0.00% | – |
| Q1 2020 | $91,000 | -54.3% | 7,812 | -41.9% | 0.00% | – |
| Q4 2019 | $199,000 | +155.1% | 13,457 | +136.3% | 0.00% | – |
| Q3 2019 | $78,000 | +457.1% | 5,694 | +436.2% | 0.00% | – |
| Q2 2019 | $14,000 | – | 1,062 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 3,156,699 | $15,689,000 | 7.73% |
| MPM ASSET MANAGEMENT LLC | 3,131,388 | $15,563,000 | 5.32% |
| MPM BioImpact LLC | 3,196,707 | $15,888,000 | 4.26% |
| ACUTA CAPITAL PARTNERS, LLC | 497,500 | $2,473,000 | 1.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 151,445 | $2,771,000 | 0.62% |
| Orbimed Advisors | 3,039,508 | $15,106,000 | 0.24% |
| Artal Group S.A. | 1,000,000 | $4,970,000 | 0.21% |
| Cormorant Asset Management, LP | 540,600 | $2,687,000 | 0.21% |
| DAFNA Capital Management LLC | 105,163 | $523,000 | 0.14% |
| Ikarian Capital, LLC | 117,009 | $582,000 | 0.08% |